Novavax (NVAX) Current Assets (2010 - 2026)

Novavax's Current Assets history runs 17 years deep, the most recent figure standing at $850.8 million for Q1 2026.

• In Q1 2026, Current Assets fell 1.98% year-over-year to $850.8 million; the TTM figure through Mar 2026 stood at $850.8 million (down 1.98% YoY), while the FY2025 annual figure was $978.3 million, down 13.35% from the prior year.
• Current Assets was $850.8 million for Q1 2026 at Novavax, down from $978.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $2.3 billion in Q1 2022 to a low of $727.1 million in Q1 2024.
• Historically, Current Assets has averaged $1.2 billion across 5 years, with a median of $1.1 billion in 2024.
• The sharpest annual moves came in 2023 and 2025: Current Assets slumped 58.63% in 2023, then rose 19.38% in 2025.
• A 5-year view of Current Assets shows it stood at $1.7 billion in 2022, then sank by 32.85% to $1.1 billion in 2023, then dropped by 1.31% to $1.1 billion in 2024, then dropped by 13.35% to $978.3 million in 2025, then decreased by 13.03% to $850.8 million in 2026.
• The last three Current Assets figures came in at $850.8 million (Q1 2026), $978.3 million (Q4 2025), and $974.6 million (Q3 2025), per Business Quant data.